168:
904:
351:) in patients receiving the highest dose. No health risks were found in subjects receiving either 0.5 or 1 mg of bapineuzumab. Patients who have been receiving or have been scheduled to receive the highest dose will be either removed from the trials or switched to lower doses.
897:
890:
642:
The vigour of international research on immunotherapy for AD provides significant hope for a strong therapeutic lead for the escalating number of individuals who will develop this otherwise incurable condition.
300:(Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. In previous clinical trials for vaccination against human beta amyloid, called AN-1792, patients with Alzheimer's disease using
292:
Bapineuzumab has been shown to recognise the extreme N-terminal 5 residues of Aβ peptide in a helical conformation (4HIX.pdb) stabilized by internal hydrogen bonds involving the first three amino acids.
826:
79:
238:
590:
278:. However, in 2012 it failed to produce significant cognitive improvements in patients in two major trials, despite lowering key biomarkers of AD, amyloid brain plaque and
688:"Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy"
855:
654:
1505:
428:
34:
1490:
1446:
348:
344:
630:
1500:
1495:
882:
655:"Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease"
263:
977:
136:
662:
1463:
913:
865:
738:
674:
Elan and Wyeth plan to continue all four studies in the previously disclosed bapineuzumab Phase 3 clinical program
534:"Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation"
1102:
1097:
443:
787:
496:
1451:
400:
163:
1358:
385:
271:
358:
in
Alzheimer's patients has been called into question, although such drugs may still be effective for
545:
384:Élan announced that Johnson & Johnson, on July 16, 2013, had discontinued Phase 2 testing of the
370:
329:
279:
301:
286:
100:
44:
27:
1334:
1236:
1135:
1006:
860:
831:
622:
602:
305:
719:
614:
571:
1143:
709:
699:
658:
606:
561:
553:
180:
109:
145:
404:
167:
763:
549:
1457:
1112:
714:
687:
566:
533:
396:
325:
267:
813:
Phase 2 testing of the subcutaneous formulation of bapineuzumab is to be discontinued.
514:
1484:
1428:
1387:
1197:
1031:
610:
439:
355:
333:
332:
affiliate acquired a substantial portion of Élan's assets related to the
Alzheimer's
156:
626:
469:
1423:
1314:
1309:
1251:
1192:
1182:
1167:
1162:
474:
381:
in two late-stage trials in patients who had mild to moderate
Alzheimer's disease.
297:
66:
1407:
1373:
1339:
1329:
1304:
1207:
1202:
1157:
1152:
1148:
1125:
1076:
1036:
963:
374:
359:
282:
1402:
1319:
1299:
1278:
1273:
1241:
1177:
1172:
1066:
1061:
1051:
1046:
1041:
1026:
1021:
992:
958:
408:
377:
formulation of bapineuzumab. Testing showed the drug did not work better than
366:
219:
120:
704:
20:
1344:
1324:
1268:
1256:
1246:
1221:
1187:
1120:
1081:
1071:
1056:
942:
937:
304:
had positive outcomes with removal of plaques, but 6% of subjects developed
49:
723:
618:
575:
336:
program, which Elan had shared with Wyeth. The program is continuing with
1263:
275:
812:
768:
378:
317:
61:
557:
362:
if given to individuals who have not yet developed clinical symptoms.
337:
316:
Bapineuzumab was being co-developed by the pharmaceutical companies
321:
53:
922:
886:
916:
for bone, musculoskeletal, circulatory, and neurologic systems
270:
and may have potential therapeutic value for the treatment of
856:"The Corruption of Sid Gilman-How a top U-M doc lost his way"
591:"Vaccination strategies for Alzheimer's disease: A new hope?"
497:"Pfizer, J&J scrap Alzheimer's research as drug fails"
788:"Pfizer, J&J scrap Alzheimer's studies as drug fails"
343:
Bapineuzumab was the first antibody to be found to cause
532:
Miles LA, Crespi GA, Doughty L, Parker MW (2013-02-18).
245:
515:"Alzheimer's disease drug shelved after trial failure"
347:, including an accumulation of fluid in brain tissue (
1416:
1395:
1386:
1366:
1357:
1287:
1229:
1220:
1134:
1111:
1090:
1014:
1005:
985:
976:
951:
930:
921:
470:"New Alzheimer's drugs might help prevent glaucoma"
218:
179:
174:
155:
135:
119:
99:
94:
78:
73:
60:
43:
33:
26:
764:"New theory of Alzheimer's explains drug failures"
739:"Drug Makers Stop Top Dosage in Alzheimer's Trial"
686:DiFrancesco JC, Longoni M, Piazza F (2015-09-25).
411:of the cancellation of bapineuzumab's testing.
108:
898:
827:"Ex-SAC Trader Convicted of Securities Fraud"
825:Stevenson A, Goldstein M (February 7, 2014).
8:
589:Woodhouse A, Dickson TC, Vickers JC (2007).
19:
1392:
1363:
1226:
1011:
982:
927:
905:
891:
883:
781:
779:
166:
713:
703:
565:
144:
815:Elan Corporation. Retrieved 2013-08-13.
419:
373:said they are ending development of an
157:
18:
403:, was convicted in February 2014 of
345:amyloid-related imaging abnormalities
7:
296:Bapineuzumab is an antibody to the
1506:Anti-amyloid monoclonal antibodies
354:The efficacy of drugs targeted to
14:
743:Drug Discovery & Development
611:10.2165/00002512-200724020-00003
340:, which acquired Wyeth in 2009.
197:
191:
1491:Drugs not assigned an ATC code
772:. Chicago: Reuters. p. 2.
762:Steenhuysen J (May 12, 2010).
407:on news passed by neurologist
209:
203:
185:
1:
427:Brandt C (Fall–Winter 2012).
388:formulation of bapineuzumab.
264:humanized monoclonal antibody
786:Berkrot B (August 7, 2012).
661:. 2008-06-17. Archived from
328:in December 2007. In 2008 a
737:Pogatchnik S (2009-04-02).
495:Berkrot B (7 August 2012).
308:and the trial was stopped.
1524:
438:. The Penn Memory Center (
429:""Team Babcock's" journey"
175:Chemical and physical data
1501:Drugs developed by Pfizer
1441:
235:
1496:Drugs developed by Wyeth
854:Betzold M (2013-01-26).
705:10.3389/fneur.2015.00207
468:Sample I (2007-08-07).
401:S.A.C. Capital Advisors
1359:Angiogenesis inhibitor
692:Frontiers in Neurology
442:): 1–3. Archived from
371:Johnson & Johnson
330:Johnson & Johnson
550:2013NatSR...3E1302M
449:on 28 February 2014
365:On August 6, 2012,
302:active immunization
280:hyperphosphorylated
272:Alzheimer's disease
28:Monoclonal antibody
23:
1468:Never to phase III
1237:Anti-amyloid drugs
861:Ann Arbor Observer
832:The New York Times
603:Adis International
538:Scientific Reports
306:aseptic meningitis
1478:
1477:
1437:
1436:
1382:
1381:
1353:
1352:
1216:
1215:
1001:
1000:
972:
971:
657:(Press release).
595:Drugs & Aging
558:10.1038/srep01302
266:that acts on the
253:
252:
16:Chemical compound
1513:
1393:
1364:
1227:
1144:Alacizumab pegol
1012:
983:
928:
907:
900:
893:
884:
878:
877:
875:
873:
864:. Archived from
851:
845:
844:
842:
840:
822:
816:
810:
804:
803:
801:
799:
783:
774:
773:
759:
753:
752:
750:
749:
734:
728:
727:
717:
707:
683:
677:
676:
671:
670:
659:Elan Corporation
651:
645:
644:
639:
638:
629:. Archived from
586:
580:
579:
569:
529:
523:
522:
521:. 7 August 2012.
511:
505:
504:
492:
486:
485:
483:
482:
465:
459:
458:
456:
454:
448:
433:
424:
326:Phase III trials
249:
248:
241:
230:
228:
211:
205:
199:
193:
187:
170:
159:
148:
112:
24:
22:
1523:
1522:
1516:
1515:
1514:
1512:
1511:
1510:
1481:
1480:
1479:
1474:
1473:
1458:Clinical trials
1433:
1412:
1378:
1349:
1283:
1212:
1130:
1107:
1086:
997:
978:Musculoskeletal
968:
947:
917:
911:
881:
871:
869:
853:
852:
848:
838:
836:
824:
823:
819:
811:
807:
797:
795:
785:
784:
777:
761:
760:
756:
747:
745:
736:
735:
731:
685:
684:
680:
668:
666:
653:
652:
648:
636:
634:
588:
587:
583:
531:
530:
526:
513:
512:
508:
494:
493:
489:
480:
478:
467:
466:
462:
452:
450:
446:
431:
426:
425:
421:
417:
405:insider trading
394:
392:Insider trading
314:
244:
242:
239:(what is this?)
236:
226:
224:
214:
208:
202:
196:
190:
151:
131:
115:
90:
17:
12:
11:
5:
1521:
1520:
1517:
1509:
1508:
1503:
1498:
1493:
1483:
1482:
1476:
1475:
1472:
1471:
1470:
1469:
1466:
1455:
1449:
1443:
1442:
1439:
1438:
1435:
1434:
1432:
1431:
1426:
1420:
1418:
1414:
1413:
1411:
1410:
1405:
1399:
1397:
1390:
1384:
1383:
1380:
1379:
1377:
1376:
1370:
1368:
1361:
1355:
1354:
1351:
1350:
1348:
1347:
1342:
1337:
1332:
1327:
1322:
1317:
1312:
1307:
1302:
1297:
1291:
1289:
1285:
1284:
1282:
1281:
1276:
1271:
1266:
1261:
1260:
1259:
1254:
1249:
1244:
1233:
1231:
1224:
1218:
1217:
1214:
1213:
1211:
1210:
1205:
1200:
1195:
1190:
1185:
1180:
1175:
1170:
1165:
1160:
1155:
1146:
1140:
1138:
1132:
1131:
1129:
1128:
1123:
1117:
1115:
1109:
1108:
1106:
1105:
1100:
1094:
1092:
1088:
1087:
1085:
1084:
1079:
1074:
1069:
1064:
1059:
1054:
1049:
1044:
1039:
1034:
1029:
1024:
1018:
1016:
1009:
1003:
1002:
999:
998:
996:
995:
989:
987:
980:
974:
973:
970:
969:
967:
966:
961:
955:
953:
949:
948:
946:
945:
940:
934:
932:
925:
919:
918:
912:
910:
909:
902:
895:
887:
880:
879:
846:
817:
805:
775:
754:
729:
678:
646:
581:
524:
506:
487:
460:
418:
416:
413:
399:, formerly of
397:Mathew Martoma
393:
390:
313:
310:
268:nervous system
251:
250:
233:
232:
222:
216:
215:
212:
206:
200:
194:
188:
183:
177:
176:
172:
171:
161:
153:
152:
150:
149:
141:
139:
133:
132:
130:
129:
125:
123:
117:
116:
114:
113:
105:
103:
97:
96:
92:
91:
89:
88:
84:
82:
76:
75:
71:
70:
64:
58:
57:
47:
41:
40:
39:Whole antibody
37:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1519:
1518:
1507:
1504:
1502:
1499:
1497:
1494:
1492:
1489:
1488:
1486:
1467:
1465:
1462:
1461:
1459:
1456:
1453:
1450:
1448:
1445:
1444:
1440:
1430:
1429:Landogrozumab
1427:
1425:
1422:
1421:
1419:
1415:
1409:
1406:
1404:
1401:
1400:
1398:
1394:
1391:
1389:
1388:Growth factor
1385:
1375:
1372:
1371:
1369:
1365:
1362:
1360:
1356:
1346:
1343:
1341:
1338:
1336:
1333:
1331:
1328:
1326:
1323:
1321:
1318:
1316:
1313:
1311:
1308:
1306:
1303:
1301:
1298:
1296:
1293:
1292:
1290:
1286:
1280:
1277:
1275:
1272:
1270:
1267:
1265:
1262:
1258:
1255:
1253:
1250:
1248:
1245:
1243:
1240:
1239:
1238:
1235:
1234:
1232:
1228:
1225:
1223:
1219:
1209:
1206:
1204:
1201:
1199:
1198:Ralpancizumab
1196:
1194:
1191:
1189:
1186:
1184:
1181:
1179:
1176:
1174:
1171:
1169:
1166:
1164:
1161:
1159:
1156:
1154:
1150:
1147:
1145:
1142:
1141:
1139:
1137:
1133:
1127:
1124:
1122:
1119:
1118:
1116:
1114:
1110:
1104:
1101:
1099:
1096:
1095:
1093:
1089:
1083:
1080:
1078:
1075:
1073:
1070:
1068:
1065:
1063:
1060:
1058:
1055:
1053:
1050:
1048:
1045:
1043:
1040:
1038:
1035:
1033:
1032:Ascrinvacumab
1030:
1028:
1025:
1023:
1020:
1019:
1017:
1013:
1010:
1008:
1004:
994:
991:
990:
988:
984:
981:
979:
975:
965:
962:
960:
957:
956:
954:
950:
944:
941:
939:
936:
935:
933:
929:
926:
924:
920:
915:
908:
903:
901:
896:
894:
889:
888:
885:
868:on 2014-02-28
867:
863:
862:
857:
850:
847:
834:
833:
828:
821:
818:
814:
809:
806:
793:
789:
782:
780:
776:
771:
770:
765:
758:
755:
744:
740:
733:
730:
725:
721:
716:
711:
706:
701:
697:
693:
689:
682:
679:
675:
665:on 2013-01-22
664:
660:
656:
650:
647:
643:
633:on 2013-01-16
632:
628:
624:
620:
616:
612:
608:
604:
600:
596:
592:
585:
582:
577:
573:
568:
563:
559:
555:
551:
547:
543:
539:
535:
528:
525:
520:
516:
510:
507:
502:
498:
491:
488:
477:
476:
471:
464:
461:
445:
441:
440:Penn Medicine
437:
430:
423:
420:
414:
412:
410:
406:
402:
398:
391:
389:
387:
382:
380:
376:
372:
368:
363:
361:
357:
356:brain plaques
352:
350:
346:
341:
339:
335:
334:immunotherapy
331:
327:
323:
319:
311:
309:
307:
303:
299:
294:
290:
288:
284:
281:
277:
274:and possibly
273:
269:
265:
261:
257:
247:
240:
234:
223:
221:
217:
184:
182:
178:
173:
169:
165:
162:
160:
158:ECHA InfoCard
154:
147:
143:
142:
140:
138:
134:
127:
126:
124:
122:
118:
111:
107:
106:
104:
102:
98:
93:
86:
85:
83:
81:
77:
74:Clinical data
72:
68:
65:
63:
59:
55:
51:
48:
46:
42:
38:
36:
32:
29:
25:
1424:Domagrozumab
1315:Galcanezumab
1310:Fremanezumab
1295:Bapineuzumab
1294:
1252:Gantenerumab
1193:Idarucizumab
1183:Etaracizumab
1168:Caplacizumab
1163:Brolucizumab
870:. Retrieved
866:the original
859:
849:
839:February 22,
837:. Retrieved
835:. p. A1
830:
820:
808:
796:. Retrieved
791:
767:
757:
746:. Retrieved
742:
732:
695:
691:
681:
673:
667:. Retrieved
663:the original
649:
641:
635:. Retrieved
631:the original
598:
594:
584:
541:
537:
527:
518:
509:
500:
490:
479:. Retrieved
475:The Guardian
473:
463:
451:. Retrieved
444:the original
435:
422:
395:
386:subcutaneous
383:
364:
353:
342:
324:and entered
315:
298:beta-amyloid
295:
291:
259:
258:(nicknamed "
256:Bapineuzumab
255:
254:
243:
237:
67:beta-amyloid
21:Bapineuzumab
1454:from market
1408:Trevogrumab
1374:Ranibizumab
1340:Solanezumab
1335:Semorinemab
1330:Refanezumab
1305:Eptinezumab
1208:Vanucizumab
1203:Tadocizumab
1158:Bococizumab
1153:Ranibizumab
1149:Bevacizumab
1126:Volociximab
1077:Ramucirumab
1037:Bentracimab
1007:Circulatory
964:Romosozumab
914:Monoclonals
872:24 February
544:(3): 1302.
375:intravenous
360:prophylaxis
283:tau protein
231: g·mol
164:100.133.214
110:648895-38-9
95:Identifiers
1485:Categories
1403:Bimagrumab
1320:Ozanezumab
1300:Crenezumab
1279:Opicinumab
1274:Fulranumab
1242:Aducanumab
1222:Neurologic
1178:Emicizumab
1173:Demcizumab
1067:Nesvacumab
1062:Inclacumab
1052:Evolocumab
1047:Evinacumab
1042:Enoticumab
1027:Alirocumab
1022:Abelacimab
993:Stamulumab
959:Blosozumab
794:. New York
748:2009-04-16
669:2008-06-18
637:2010-07-27
605:: 107–19.
481:2008-06-18
415:References
409:Sid Gilman
367:Pfizer Inc
220:Molar mass
146:NC11WKO35D
121:ChemSpider
101:CAS Number
1464:Phase III
1452:Withdrawn
1417:Humanized
1367:Humanized
1345:Tanezumab
1325:Ponezumab
1288:Humanized
1269:Fasinumab
1257:Lecanemab
1247:Donanemab
1188:Faricimab
1136:Humanized
1121:Abciximab
1103:Imciromab
1098:Biciromab
1082:Rinucumab
1072:Orticumab
1057:Icrucumab
952:Humanized
943:Denosumab
938:Burosumab
798:August 7,
50:Humanized
1264:Erenumab
1113:Chimeric
724:26441825
627:28279428
619:17313199
576:23416764
519:BBC News
276:glaucoma
262:") is a
246:(verify)
80:ATC code
792:Reuters
769:Reuters
715:4585101
698:: 207.
567:3575012
546:Bibcode
501:Reuters
436:InSight
379:placebo
312:Testing
181:Formula
1447:WHO-EM
722:
712:
625:
617:
574:
564:
369:. and
349:ARIA-E
338:Pfizer
62:Target
52:(from
45:Source
1396:Human
1230:Human
1091:Mouse
1015:Human
986:Human
931:Human
623:S2CID
601:(2).
453:1 Feb
447:(PDF)
432:(PDF)
322:Wyeth
195:10018
54:mouse
923:Bone
874:2014
841:2014
800:2012
720:PMID
615:PMID
572:PMID
455:2014
320:and
318:Élan
260:bapi
207:2026
201:1734
189:6466
137:UNII
128:none
87:none
69:(Aβ)
35:Type
710:PMC
700:doi
607:doi
562:PMC
554:doi
287:CSF
285:in
229:.02
227:874
225:145
1487::
1460::
858:.
829:.
790:.
778:^
766:.
741:.
718:.
708:.
694:.
690:.
672:.
640:.
621:.
613:.
599:24
597:.
593:.
570:.
560:.
552:.
540:.
536:.
517:.
499:.
472:.
434:.
289:.
213:44
1151:/
906:e
899:t
892:v
876:.
843:.
802:.
751:.
726:.
702::
696:6
609::
578:.
556::
548::
542:3
503:.
484:.
457:.
210:S
204:O
198:N
192:H
186:C
56:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
